Foresee Pharmaceuticals Co (ROCO:6576) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6576 Foresee Pharmaceuticals Co Ltd ROCO:6576
59 GF Score
Price NT$79.20
GF Value NT$84.14
Valuation Fairly Valued
! 10 Warning Signs
View Full Analysis

What is Foresee Pharmaceuticals Co Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

ROCO:6576
59GF Score
Foresee Pharmaceuticals Co Ltd ROCO:6576
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Foresee Pharmaceuticals Co (ROCO:6576) Overvalued in 2026?

Based on GuruFocus' analysis, Foresee Pharmaceuticals Co stock appears to be undervalued. The current stock price of NT$79.20 is trading 5.9% below its estimated GF Value™ of NT$84.14. GuruFocus considers Foresee Pharmaceuticals Co to be Fairly Valued.

Key valuation signals for ROCO:6576:

  • Dividends Received:
  • GF Value™: NT$84.14 vs. price of NT$79.20 (5.9% below fair value)
  • GF Score™: 59/100 with 10 warning signs

No single metric tells the full story. See the ROCO:6576 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Foresee Pharmaceuticals Co Business Description

Address No. 19-3, Sanchong Road, 9th Floor-2, Nangang District, Taipei, TWN, 115
Foresee Pharmaceuticals Co Ltd main activity is applying stabilized injectable formulation (SIF) platform technology to produce products for anticancer and treatment of chronic diseases. Its pipeline includes CAMCEVI (Leuprolide, FP-001), FP-014 (Triptorelin), Aderamastat (FP-025, MMP-12 Inhibitor), Linvemastat (FP-020, MMP-12 Inhibitor), and others. The Group operates business only in a single industry of new drug development, and all of its revenue is generated from Taiwan.
59GF Score

Get the complete analysis for ROCO:6576

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$79.20
Price
NT$84.14
GF Value